Because obesity is more prevalent among individuals with low income, access and affordability to GLP-1 RAs may represent a major barrier to initiation and continued use.14,15 In addition, limited payer coverage of antiobesity medications and off-label use of antidiabetes medications, including GLP-1 RAs, still represents a major challenge for many patients.16,17,18 Finally, shortages of GLP-1 RAs may limit continued use.19 This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.